Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009

Clinical and Vaccine Immunology

Volumn 19, Issue 2, 2012, Pages 219-222

  Trotter, Caroline L ^a   Findlow, Helen ^b   Borrow, Ray ^b,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; CHILD; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROPREVALENCE; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HUMANS; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP W-135; NEISSERIA MENINGITIDIS, SEROGROUP Y; SEROEPIDEMIOLOGIC STUDIES; SERUM BACTERICIDAL ANTIBODY ASSAY; YOUNG ADULT;

EID: 84856458140     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05515-11     Document Type: Article

References (34)

1. Ala'aldeen DA, et al. 2011. Carriage of meningococci by university students, United kingdom. Emerg. Infect. Dis. 17:1762-1763.
2. Al-Mazrou Y, et al. 2005. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect. Immun. 73:2932-2939.
3. Amadou HA, et al. 2006. Prospective survey on carriage of Neisseria meningitidis and protective immunity to meningococci in schoolchildren in Niamey (Niger): focus on serogroup W135. Microbes Infect. 8:2098-2104.
4. Anonymous. 2002. Meningococcal disease, serogroup W135, Burkina Faso. Preliminary report, 2002. Wkly. Epidemiol. Rec. 77:152-155.
5. Balmer P, Borrow R. 2007. Issues surrounding standardization of meningococcal group W135 serology. Vaccine 25(Suppl. 1):A63-A68. (Pubitemid 47198931)
6. Bidmos FA, et al. 2011. Persistence, replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university student cohort. J. Clin. Microbiol. 49:506-512.
7. Borrow R. 2009. Meningococcal disease and prevention at the Hajj. Travel Med. Infect. Dis. 7:219-225.
8. Borrow R, Andrews N, Goldblatt D, Miller E. 2001. Serological basis for the use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69: 1568-1573. (Pubitemid 32187610)
9. Borrow R, Balmer P, Miller E. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23:2222-2227. (Pubitemid 40341456)
10. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. 2010. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17:840-847.
11. Campbell H, Borrow R, Salisbury D, Miller E. 2009. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl. 2):B20-B29.
12. Caugant DA, Maiden MC. 2009. Meningococcal carriage and disease-population biology and evolution. Vaccine 27(Suppl. 2):B64-B70.
13. Christensen H, May M, Bowen L, Hickman M, Trotter CL. 2010. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10:853-861.
14. Decosas J, Koama JBT. 2002. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect. Dis. 2:763-765. (Pubitemid 35434562)
15. Giardina PC, et al. 2005. Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide. Clin. Diagn. Lab. Immunol. 12:586-592. (Pubitemid 41184718)
16. Goldschneider I, Gotschlich EC, Artenstein MS. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
17. Gray SJ, et al. 2006. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol. 55:887-896. (Pubitemid 43974695)
18. Jackson LA, Wenger JD. 1993. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill. Summ. 42:21-30.
19. Kelly H, Riddell MA, Gidding HF, Nolan T, Gilbert GL. 2002. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 20:3130-3136.
20. Longworth E, et al. 2002. O-acetylation status of the capsular polysaccharides of serogroup Y and W135 meningococci isolated in the UK. FEMS Immunol. Med. Microbiol. 32:119-123. (Pubitemid 34124110)
21. Maiden MC, et al. 2008. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197:737-743. (Pubitemid 351364476)
22. Maslanka SE, et al. 1997. Standardisation and a multilaboratory comparison of Neisseria meningitidis serogroupAandCserum bactericidal assays. Clin. Diagn. Lab Immunol. 4:156-167. (Pubitemid 27130227)
23. Miller E, et al. 2010. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 375: 1100-1108.
24. Mueller JE, Borrow R, Gessner BD. 2006. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev. Vaccines 5:319-336. (Pubitemid 44167154)
25. Mueller JE, et al. 2006. Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003. J. Infect. Dis. 193:812-820.
26. Osborne K, et al. 2000. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int. J. Epidemiol. 29:362-368.
27. Ostergaard L, et al. 2009. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27:161-168.
28. Raghunathan PL, et al. 2006. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002. J. Infect. Dis. 193:607-616. (Pubitemid 43271494)
29. Rosenstein NE, et al. 1999. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180:1894-1901.
30. Snape MD, et al. 2008. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336:1487-1491. (Pubitemid 351977021)
31. Trotter C, et al. 2003. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 21:1094-1098. (Pubitemid 36139939)
32. Trotter CL, Borrow R, Andrews N, Miller E. 2008. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin. Vaccine Immunol. 15:1694-1698.
33. Trotter CL, et al. 2007. Seroprevalence of bactericidal and anti-outer membrane vesicle antibody to Neisseria meningitidis group B in England. Clin. Vaccine Immunol. 14:863-868.
34. Trotter CL, Gay NJ, Edmunds WJ. 2006. The natural history of meningococcal carriage and disease. Epidemiol. Infect. 134:556-566.